Bill Calls for Disclosure of Drug-Company Gifts to Doctors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bill Calls for Disclosure of Drug-Company Gifts to Doctors


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Washington, DC (Sept. 6)—Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) introduced the Physician Payments Sunshine Act to require pharmaceutical and biologics manufacturers to report the payments, gifts, honoraria, and trips they give to doctors. The Act would apply to manufacturers with annual gross revenues of $100 million or more. It would provide penalties of $10,000–100,000 for each failure to report payments. In addition, the legislation would require the Secretary of Health and Human Services to clearly post payment information on a special website. Grassley said the legislation draws on similar initiatives in Minnesota, Vermont, Maine, and West Virginia. 

“Right now the public has no way to know whether a doctor’s been given money that might affect prescribing habits,” Grassley said in a press release. “Whether it’s dinner at a restaurant or tens of thousands of dollars or more in fees and travel, patients shouldn’t be in the dark about whether their doctors are getting money from drug and device makers.”

Senators Claire McCaskill (D-MO), a cosponsor of the bill, said in a press release, “By requiring drug companies … to report on their gifts to doctors, we are empowering patients to talk with their doctors about the drugs they are prescribed and to learn more about the influence of the pharmaceutical industry on the practice of medicine. I believe that by bringing light to these relationships, this legislation will go far in reducing big drug companies’ influence on the business of medicine.”

Senators Chuck Schumer (D-NY), Amy Klobuchar (D-MN), and Ted Kennedy (D-MA) also are original cosponsors of the Grassley–Kohl bill. Grassley is a ranking member of the Committee on Finance, where he has conducted oversight of educational grants awarded to doctors by drug companies. Kohl chairs the Special Committee on Aging. He held a hearing in June 2007 to examine the financial relationship between physicians and the pharmaceutical industry.

Click here for Grassley’s floor statement about the bill. Click here for information about the Aging Committee hearing.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here